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ABSTRACT
The Indian Asian population accounts for a fifth of all global deaths from coronary heart disease (CHD).
CHD deaths on the Indian subcontinent have doubled since 1990, and are predicted to rise a further
50% by 2030. Reasons underlying the increased CHD mortality among Indian Asians remain unknown.
Although conventional cardiovascular risk factors contribute to CHD in Indian Asians as in other
populations, these do not account for their increased risk. Type-2 diabetes, insulin resistance and
related metabolic disturbances are more prevalent amongst Indian Asians than Europeans, and have
been proposed as major determinants of higher CHD risk among Indian Asians. However, this view is
not supported by prospective data. Genome-wide association studies have not identified differences in
allele frequencies or effect sizes in known loci to explain the increased CHD risk in Indian Asians.
Limited knowledge of mechanisms underlying higher CHD risk amongst Indian Asians presents a major
obstacle to reducing the burden of CHD in this population. Systems biology approaches such as
genomics, epigenomics, metabolomics and transcriptomics, provide a non-biased approach for
discovery of novel biomarkers and disease pathways underlying CHD. Incorporation of these ‘omic’
approaches in prospective Indian Asian cohorts such as the London Life Sciences Population Study
(LOLIPOP) provide an exciting opportunity for the identification of new risk factors underlying CHD in
this high risk population.
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INTRODUCTION
Coronary heart disease is the leading cause of death worldwide, responsible for over 7 million deaths
annually. Indian Asians (people originating from India, Pakistan, Bangladesh and Sri Lanka) comprise
one quarter of the globe’s population and are at high risk of developing CHD. Recent estimates from
the Global Burden of Disease (GBD) 2010 Study1 indicate that CHD deaths are highest in South Asia,
increasing by 87.8% between 1990 and 2010, second only to East Asia (Table 1). This is predicted to
increase a further 50% by 2030.2 CHD prevalence is presently twice as high in urban compared to
rural India (10–12% vs. 4–5%).3,4 With CHD rates increasing more quickly in urban vs. rural areas
(Figure 1), and compounded by the current rapid rate of urbanization in India,5 this may result in an
underestimation of CHD mortality projections. India experiences amongst the highest number of
potentially productive life years lost due to cardiovascular disease; 9.2 million years in 2000,
expected to double to 17.9 million years by 2030.6 The World Health Organisation estimated that India
lost 8.7 billion US dollars in national income due to combined mortality from CHD, stroke and diabetes
in 2005.7
Epidemiology of CHD in Indian Asians
High CHD mortality rates have also been reported in migrant Indian Asian populations in England and
Wales,8,9 the United States,10,11 Canada,12,13 Singapore,14,15 Mauritius,16,17 South Africa,18 and Trinidad19
(Table 2). In the UK, Indian Asians have,2-fold higher CHD mortality compared to Europeans. Overall
CHD mortality rates have fallen in most minority ethnic groups residing in England and Wales since
1980,8 including those born on the Indian subcontinent. Importantly, increasing mortality rate ratio
figures for Indian Asians compared to Europeans suggest that the overall observed decline in CHD
mortality is slower amongst UK Indian Asian populations (Table 3).
Conventional CHD risk factors are known to have a pivotal role in CHD in all populations, including
Indian Asians (Table 4). INTERHEART, a case-control study of 15,152 first myocardial infarction cases
and 14,820 controls recruited from 52 countries20 (including 2,171 Indian Asian cases and 2,573
controls), compared hazard ratios and population-attributable risk fractions (PAR) for major CHD risk
factors (smoking, hypertension, diabetes, central obesity, dyslipidaemia, physical activity level,
psychosocial factors, alcohol, fruit and vegetable consumption). In the INTERHEART study, these nine
modifiable risk factors collectively account for ,88% of CHD in Indian Asians, similar to other
populations (Table 5). INTERHEART was not designed to address reasons underlying differences in CHD
risk between population groups.
Table 1. Number of CHD deaths in different regions (% change in number of deaths from previous
available total). Data derived from GBD 2010.1 GBD definition of countries in South Asia comprises
Afghanistan, Bangladesh, Bhutan, India, Nepal and Pakistan. East Asia comprises China,
North Korea, and Taiwan.
Region 1990 2010 % change
Asia
East Asia 472,158 992,163 þ110.1%
South Asia 704,833 1,323,551 þ87.8%
South East Asia 215,719 383,323 þ77.7%
Asia Pacific, High-income 113,347 166,853 þ47.2%
Central Asia 138,157 184,167 þ33.3%
Australasia 42,128 37,738 210.4%
Europe
Eastern Europe 834,783 1,115,213 þ33.6%
Central Europe 331,497 344,139 þ3.8%
Western Europe 929,366 745,590 219.8%
Africa
North Africa & Middle East 263,978 418,019 þ58.4%
Sub-Saharan Africa 144,713 217,397 þ50.2%
America
South America 275,187 422,584 þ53.6%
North America, High-income 703,057 619,377 211.9%
Others
Oceania 2,552 4,581 þ79.5%
Caribbean 40,315 54,576 þ35.4%
Global 5,211,790 7,029,270 þ34.9%
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Previous studies showed that the differences in prevalence of smoking, hypertension, and
dyslipidaemia were not consistently pointing to higher risk amongst UK Indian Asian sub-groups
compared to Europeans. These studies argued that conventional risk factors did not explain the,40%
excess CHD mortality among Indian Asians.21,22 In contrast, type-2 diabetes (T2D), insulin resistance
and related metabolic disturbances (i.e. high triglycerides, low high-density lipoprotein cholesterol,
central obesity) were found to be more prevalent amongst Indian Asians than Europeans23; in
multivariate regression models, insulin resistance accounted for ,70% of the excess risk of major
Q waves (representing CHD mortality risk) in Indian Asians compared to Europeans.23 Most previous
studies amongst Indian Asians have been either cross-sectional or case-control in design and hence
the contribution of risk factors to incident CHD has not been possible to assess in this population.
Thus reasons underlying the excess risk of CHD amongst Indian Asians compared to Europeans, and
other population groups, remain poorly understood.
The Southall and Brent Revisited (SABRE) Study was a prospective comparison of CHD mortality
among UK Indian Asian and European men24 (n ¼ 1,420 and 1,787 respectively). SABRE confirmed a
,2-fold excess CHD risk amongst Indian Asian men, which persisted after adjustment for CHD risk
factors including obesity, diabetes, insulin resistance, blood lipids, blood pressure and smoking
(Table 6). These prospective data do not support the widely held view that the excess CHD risk
amongst Indian Asians compared to Europeans is largely attributable to central adiposity, insulin
resistance or diabetes. However, SABRE did not investigate the role of diet, physical activity, or genetic
risk factors and did not study women.
The LOLIPOP study was established to investigate the reasons underlying higher susceptibility
among Indian Asians to diabetes and cardiovascular disease, compared to Europeans. LOLIPOP is
a prospective cohort of ,24,000 Indian Asian and European men and women. Participants were
recruited from the lists of local General Practitioners, thus providing a representative sample of the
population living in West London. Participants have had detailed clinical cardiovascular (including
12-lead electrocardiogram) and biochemical characterisation, with assessment of diet and physical
Figure 1. Secular trends in the prevalence of coronary heart disease in rural and urban India (adapted from
Gupta et al.3).
Table 2. Age-standardised CHD mortality (per 100,000) for populations in different countries over
the listed period.
Country Malaysia South Africa Canada Singapore
England &
Wales
Period
1968–1993 1989 1989–1993 1991–1999 1999–2003
Population Male Female Male Female Male Female Male Female Male Female
Indian Asian 367 74 226 113 247 120 165 73 242 84
European – – 139 55 260 90 – – 133 39
Chinese 106 31 – – 90 37 63 25 – –
Black – – 11 8 – – – – – –
Malay 142 33 – – – – 128 71 – –
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activity. Blood samples have been stored for future analysis. Subsets of participants have genome-
wide scans (n , 20,000), whole genome (n , 400) or whole exome sequencing (n , 2,000),
metabolome-wide (n , 15,000) and epigenome-wide scans (n , 3,300).25–27 A representative
LOLIPOP sample of Indian Asians (n , 1,000) and Europeans (n , 1,000) have also had
echocardiography,28 24hr blood pressure, 24hr holter monitor, cardiac computed tomography (calcium
scores), carotid intima media thickness29 (with plaque characterisation), to examine the role of
subclinical risk factors to high rates of CHD in Indian Asians.
Characteristics of LOLIPOP participants are shown in Table 7. Indian Asians have a ,2-fold higher
prevalence of CHD compared to Europeans which is evident at all age-groups (Figure 2). In multivariate
regression analysis, the odds ratio (OR) for CHD was 2.11 (95% C.I. 1.86–2.40, p , 0.001) amongst
Indian Asians compared to Europeans after adjustment for age, sex and conventional CHD risk factors
(Table 8). After additional correction for insulin resistance, triglycerides and HDL cholesterol, a nearly
2-fold excess risk of CHD remained amongst Indian Asians compared to Europeans (OR 1.81, 95% C.I.
1.54–2.11, p , 0.001). LOLIPOP results therefore show that the higher risk of CHD amongst UK Indian
Asians is not explained by conventional risk factors, insulin resistance and related metabolic
disturbances.
LOLIPOP participants are completing ,10 year follow-up for cardiovascular events as well as other
major health outcomes. Ascertainment of events is being carried out through a multi-faceted approach
including events occurring in primary care, hospital events, face-to-face follow-up, and national
mortality records. This effort is expected to yield in excess of 2,000 cardiovascular events, making it
possible to conduct the first well-powered investigation into the role of established, emerging and
novel risk factors to incident cardiovascular events amongst Indian Asians, and help identify the
reasons underlying their excess of CHD risk compared to Europeans.
Genomic, epigenomic and metabolomic approaches to identify novel CHD risk factors among
Indian Asians
Studies in Indian Asian families show that cardiovascular risk factors are heritable.30 Genome-wide
association studies (GWAS) amongst Indian Asians and Europeans together identify a total of 51 single
nucleotide polymorphisms (SNPs, from 45 loci) associated with CHD.31–34 These individual variants
each have a modest effect size, with odds ratios of 1.05–1.30 per risk allele copy, and in aggregate
account for only a small proportion of the total predicted genetic variance. We have found no
Table 3. Mortality rate ratios (95% confidence intervals) for UK Indian Asians (mortality rates for
persons born in England and Wales taken as reference).7
Mortality Rate Ratios 1979–1983 1989–1993 1999–2003
India (male) 1.40 (1.35–1.45) 1.41 (1.36–1.45) 1.44 (1.38–1.50)
Pakistan (male) 1.14 (1.04–1.24) 1.52 (1.43–1.60) 1.93 (1.82–2.03)
Bangladesh (male) 1.36 (1.14–1.58) 1.69 (1.51–1.85) 2.11 (1.90–2.31)
India (female) 1.58 (1.47–1.68) 1.71 (1.61–1.81) 1.84 (1.72–1.95)
Pakistan (female) 1.14 (0.85–1.42) 1.33 (1.14–1.53) 2.45 (2.21–2.68)
Table 4. Odds ratios for acute myocardial infarction in the INTERHEART study.20
Risk
factor
South
Asian*
Western
European
Central &
Eastern European Overall
Smoking# 2.43 1.96 1.92 2.27
Hypertension@ 2.89 2.22 2.11 2.48
Diabetes@ 2.48 4.29 2.61 3.08
Central obesity^ 2.43 4.50 1.74 2.24
Psychosocial factors$ 2.15 1.14 3.92 2.51
ApoB/A1 ratio& 3.81 3.76 2.20 3.87
* South Asian defined as persons from Bangladesh, India, Nepal, Pakistan or Sri Lanka.
# Includes current (individuals who smoked any tobacco in the previous 12 months) and former smokers.
^ Upper tertile vs. lowest tertile (waist-hip ratio of 0·90 and 0·95 in men and 0·83 and 0·90 in women used to divide participants into tertiles).
$ A model-dependent index combining positive exposure to depression, perceived stress at home or work (general stress), low locus of control,
and major life events, all referenced against non-exposure for all five factors
& ApoB/A1 ratio (top vs. lowest quintile).
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significant differences in either allele frequencies or odds ratios for these known CHD SNPs (discovered
in Europeans) between Indian Asians and Europeans (Figure 3). Our results therefore imply that
reported genetic variants thus far do not account for the increased risk of CHD amongst Indian Asians
compared to Europeans. However, these findings do not exclude a role for genetic factors since the
GWAS approach is not well designed to identify either low frequency or rare variants, which could make
an important contribution to the “missing heritability”.35 Furthermore, the available GWAS arrays are
based on HapMap data36 from predominantly European populations and thus do not capture Indian
Asian-specific genetic variation contributing to CHD. Previous studies provide evidence for
population-specific genetic variation increasing susceptibility to cardiovascular disease in Indian
Asians. A 25-base pair deletion in the gene encoding cardiac myosin binding protein C (MYBPC3),
found in ,4% of the population of Indian Asian ancestry, but absent amongst Europeans, is
associated with an ,7-fold increased risk of heart failure in Indian populations.37
The lack of a systematic catalogue of Indian Asian-specific genetic variation is a major limitation
to the identification of the genetic factors contributing to CHD in this population, and underlies the
strategy of whole genome (WGS) and whole exome sequencing (WES) amongst Indian Asians
participating in the LOLIPOP study. The 1000 Genomes project is actively extending the catalogue of
known human variants down to a frequency of ,1% through WGS of target populations. LOLIPOP has
carried out WGS (n , 400) and WES (n , 2,000) in order to catalogue Indian Asian-specific genetic
variation. Results of this effort will help in the design of future studies assessing the contribution of
Indian Asian-specific variants (including low frequency and rare variants) to the excess risk of CHD
amongst Indian Asians compared to Europeans.
Table 5. Population attributable risk (%) for acute MI associated with nine modifiable risk factors
amongst South Asians in INTERHEART.20
South Asians (Cases ¼ 2,171,
Controls ¼ 2,573)
Population attributable risk
All Males Females
Smoking (current or previous) 37.4 42.0 7.1
Fruits and Vegetables 18.3 16.0 30.6
Exercise£ 27.1 25.5 45.0
Alcohol# 25.5 25.7 26.0
Hypertension* 19.3 17.8 28.9
Type-2 diabetes* 11.8 10.5 20.5
Central obesity 37.7 36.0 48.7
Psychosocial factors 15.9 13.9 29.2
ApoB/A1 ratio 58.7 60.2 52.1
All nine risk factors 89.4 88.4 99.3
£ Deemed physically active if participants were regularly involved in moderate (walking, cycling, or gardening) or strenuous exercise
(jogging, football, and vigorous swimming) for $4 hours per week.
# Regular consumption defined as alcohol intake three or more times a week.
* Self-reported.
Table 6. CHD mortality amongst 1,420 Indian Asian and 1,787 European men participating in the
SABRE study. Study period from 1988–2006.24
Risk factors# Hazard ratio (95% CI) P
Age 1.82 (1.34–2.47) ,0.001
Age þ smoking þ total cholesterol 2.29 (1.63–3.23) ,0.001
Age, smoking, total cholesterol þ HDL cholesterol
þ systolic blood pressure þ diabetes
1.76 (1.23–2.51) 0.002
Age, smoking, total cholesterol þ HDL cholesterol
þ systolic blood pressure þ HOMA-IR
1.90 (1.33–2.74) ,0.001
Age, smoking, total cholesterol þ component features
of metabolic syndrome#
1.88 (1.32–2.67) ,0.001
Age, smoking, total cholesterol þ composite definition
of IDF metabolic syndrome*
2.20 (1.54–3.14) ,0.001
#Metabolic syndrome components entered as continuous variables (waist circumference, HDL cholesterol, triglycerides, fasting glucose, systolic
blood pressure).
* IDF metabolic syndrome definition: waist circumference $94 cm European men or $90 cm Indian Asian men, plus any 2 of the following 4
factors: (1) fasting glucose $5.6 mmol/l or previously diagnosed diabetes; (2) triglycerides $1.7 mmol/l or specific treatment for this lipid
abnormality; (3) HDL-cholesterol , 1.03 mmol/l in men or specific treatment for this lipid abnormality; or (4) high blood pressure ($130/$85
mmHg, or antihypertensive medication use). All models adjusted for socio-economic status.
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Epigenetic factors which are known to alter gene function, but are not the result of changes in the
DNA sequence,38 are increasingly considered to have a role in susceptibility to cardiovascular disease.
Epigenetic regulation of gene function is determined by reversible molecular processes such as histone
binding of DNA and methylation at cytosine residues, both of which influence transcription factor
binding and accessibility of DNA to the polymerase enzymes. The role of epigenetics is well established
in cellular differentiation. More recent evidence suggests that epigenetic patterns of gene regulation
may also occur in response to environmental insults, and underlie susceptibility to future disease.
In the context of cardiovascular disease, several studies suggest that in utero or early life exposure to a
poor nutritional environment may predispose to the development of cardiovascular disease in adult
life. More than 96% of low birth-weight occurs in the developing world, with highest incidence in Indian
Asians (7.1% of live births).39 Birth cohort studies show that maternal undernutrition, low birth-weight,
and rapid postnatal child growth are all associated with increased risk of CHD in the off-spring.40,41
These risks appear to be trans-generational raising the possibility that epigenetic mechanisms may
underlie part of the increased risk of cardiovascular disease amongst Indian Asians.42
Technological advances have enabled nuclear magnetic resonance (NMR) spectrometry to detect a
wide variety of metabolites from dietary, gut microbial, and host metabolism sources in one analytical
Table 7. Clinical characteristics of LOLIPOP participants. Results presented as mean (standard
deviation) or percentage.
Indian Asians Europeans P
n 16,774 7,032
Age (years) 50.5 (11.2) 52.3 (11.6) ,0.001
Male (%) 61.2 59.6 0.017
Coronary heart disease (%) 10.5 5.6 ,0.001
Type-2 diabetes# (%) 18.5 7.4 ,0.001
History of hypertension (%) 29.4 20.3 ,0.001
Ever Smoked (%) 18.7 57.2 ,0.001
Fasting glucose (mmol/L) 5.6 (1.6) 5.2 (1.1) ,0.001
Fasting insulin (mU/L) 10.5 (9.8) 7.6 (8.0) ,0.001
HOMA-IR$ 2.6 (3.0) 1.8 (2.2) ,0.001
Body mass index (kg/m2) 27.0 (4.7) 27.0 (5.3) 0.190
Waist-hip ratio 0.94 (0.08) 0.91 (0.08) ,0.001
Total cholesterol (mmol/L) 5.22 (1.08) 5.43 (1.09) ,0.001
HDL cholesterol (mmol/L) 1.25 (0.33) 1.39 (0.40) ,0.001
LDL cholesterol (mmol/L) 3.19 (0.90) 3.34 (0.93) ,0.001
Triglycerides (mmol/L) 1.44 (1.00) 1.25 (0.92) ,0.001
# Includes participants with undiagnosed type-2 diabetes
$ Homeostatic model assessment – insulin resistance
Figure 2. Prevalence of coronary heart disease (95% confidence interval) amongst the 16,774 UK Indian Asian
and 7,032 European participants in the LOLIPOP study.
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sweep. Bioinformatic approaches now allow combined analysis of metabolic phenotypes with
genomic, epigenomic, and transcriptomic markers providing greater insight into potential mechanisms
underlying cardiovascular disorders.43 The incorporation of these ‘omic’ markers (genomics,
metabolomics and epigenomics) into the prospective LOLIPOP study design provides an exciting
opportunity for discovery of novel risk factors and disease mechanisms underlying the excess risk
of CHD amongst the Indian Asian population.
Strategies to reduce CHD amongst Indian Asians
Reasons underlying the 2-fold increased CHD risk amongst Indian Asians compared to Europeans
remain poorly understood. The high CHD rates amongst Indian Asians nevertheless necessitate urgent
attention. Priorities should include optimal management of Indian Asians with established CHD,
treatment of those with cardiovascular risk factors, and of first degree relatives of Indian Asians with
premature CHD. Measures to improve education and management of cardiovascular risk factors in the
population are also required. Healthcare organisations and professionals need awareness of the
higher risk of CHD and adverse outcomes faced by Indian Asians. Comprehensive screening for
cardiovascular risk factors such as diabetes, hypertension and dyslipidaemia needs to be targeted in
this population. Of the available risk stratification tools, the Framingham Risk Score (FRS)44 has been
shown to underestimate CHD risk amongst Indian Asians thus limiting its usage. Modifications to
improve FRS discrimination amongst Indian Asians have been suggested, such as multiplying the FRS
by a factor of 1.4 (for males),45 or adding 10 years to the patients age.46 QRISK247 is a contemporary
cardiovascular risk prediction tool developed and independently validated in UK populations.48,49
The QRISK2 algorithm takes ethnicity and deprivation into account, and is continuously updated,
but the study population is mainly Caucasian (,1% Indian Asian). QRISK2 has not been externally
validated in Indian Asians.
Table 8. Multivariate regression analysis showing the odds ratio for coronary heart disease
amongst Indian Asians compared to Europeans in the LOLIPOP study.
Odds ratio
Model Risk factors Indian Asians vs. Europeans P
A Age þ sex 2.55 (2.26–2.87) ,0.001
B Model A þ ever smoked þ total cholesterol 2.67 (2.33–3.06) ,0.001
C Model B þ history of hypertension þ type-2 diabetes 2.23 (1.94–2.57) ,0.001
D Model C þ body mass index þ waist-hip ratio 2.28 (1.97–2.63) ,0.001
E Model D þ triglycerides þ HDL cholesterol þ HOMA-IR# 1.81 (1.54–2.11) ,0.001
# Homeostatic model assessment – insulin resistance
Figure 3. Risk allele frequencies or effect sizes (odds ratio) of known CHD SNPs (n ¼ 51*) in Indian Asians
(LOLIPOP data) against Europeans (in published data).32–34 *Effect sizes of known CHD SNPs in European
populations available for only 26 variants; published odds ratios for other variants include Indian Asian data.
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Despite CHD being a major threat and huge public health challenge, it has attracted limited response
from governments of the Indian Subcontinent. Only 1.1% of the Gross Domestic Product was spent on
healthcare50 in India (2008-9), lower than most other emerging economies. Major inequities based on
gender, caste, geography, and social status persist.50,51 Government funding and policymakers need to
establish preventative strategies to reduce the burden of CHD and its risk factors. Additionally, major
investment is required into research aimed at understanding increased susceptibility to CHD amongst
Indian Asians.
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